FENNEC PHARMACEUTICALS INC

Explore how Fennec Pharma’s insider trades reveal confidence in its sodium thiosulfate program to curb platinum‑induced ototoxicity in children.

Insider buying at Fennec Pharma signals confidence in its platinum‑ototoxicity pipeline; a cautious yet optimistic signal for investors weighing risk‑reward.

CEO insider buys 16,695 shares of Fennec Pharma—boosting optimism amid volatile biotech market, positive sentiment, and long‑term confidence in its pipeline.

Fennec’s insider buying signals executive confidence in its otoprotective therapy pipeline and strong commercial prospects, hinting at future upside for investors.

Fennec Pharmaceuticals’ CEO settles 13,710 PSUs, boosting insider confidence amid rising stock, strong momentum, and a promising pediatric oncology pipeline.